CRBP — Corbus Pharmaceuticals Holdings, Inc.

Summary of Corbus Pharmaceuticals Q4 2020 Earnings Call

1. Key Financial Results and Metrics

• Corbus reported a cash position of approximately $127 million as of March 15, 2021, expected to fund operations into Q1 2024.
• The company anticipates a reduced cash burn rate of around $10 million per quarter, down from $21 million in the previous quarter, due to workforce reductions and completed pivotal studies.

2. Strategic Updates and Business Highlights

• Corbus is focused on maximizing the value of lenabasum, with a Phase 3 study in dermatomyositis expected to yield topline data in Q2 2021.
• The primary endpoint for the dermatomyositis study has been moved from week 52 to week 28, with all patients having completed the week 28 visit.
• The company is advancing its internal pipeline targeting the endocannabinoid system, with plans to initiate clinical studies for new drug candidates in 2022.
• Corbus is exploring external partnerships to expand its pipeline beyond the endocannabinoid system.

3. Forward Guidance and Outlook

• The company is optimistic about the upcoming data from the dermatomyositis study and its implications for future programs, including systemic sclerosis.
• Corbus plans to focus on programs with early data inflection points and is committed to bringing in external assets to complement its existing pipeline.

4. Bad News, Challenges, or Points of Concern

• There are no additional studies planned for lenabasum in cystic fibrosis, which may limit potential revenue from that indication.
• The company faces uncertainty regarding the FDA's willingness to approve drugs based on subset analyses, as highlighted by the recent approval of Roche's Actemra despite previous study failures.
• The competitive landscape remains challenging, particularly in the autoimmune disease space, as evidenced by the scrutiny surrounding lenabasum's efficacy compared to established treatments.

5. Notable Q&A Insights

• The discontinuation rate in the dermatomyositis study was reported at 8%, which is lower than expected, with 90% of eligible patients enrolling in the open-label extension.
• The company is analyzing data from the dermatomyositis study to determine next steps for the systemic sclerosis program, with timelines for updates expected in the second half of 2021.
• There is confidence in selecting candidates for the CB1 and CB2 programs, with ongoing tests indicating promising results in metabolic activity and receptor occupancy management.

Overall, Corbus Pharmaceuticals is positioned for potential growth with its clinical programs, but it must navigate competitive pressures and regulatory uncertainties.